SCHEMBL1979301

SCHEMBL1979301

COC(=O)c1ncccc1CBr

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.55
PARP1 P09874 1/20 0.49
MPO P05164 1/20 0.46
KDM4E B2RXH2 3/20 0.44
CYP1A2 P05177 1/20 0.44
MAPT P10636 1/20 0.44
BRD4 O60885 1/20 0.42
MAP2K1 Q02750 1/20 0.42
ALOX15 P16050 1/20 0.42
HTT P42858 1/20 0.42
ALDH1A1 P00352 3/20 0.41
TDP1 Q9NUW8 1/20 0.41
LMNA P02545 1/20 0.41
PKM P14618 1/20 0.40
CYP4F2 P78329 1/20 0.40
CYP4A11 Q02928 1/20 0.40
EGLN2 Q96KS0 1/20 0.40
FTO Q9C0B1 1/20 0.40
NPSR1 Q6W5P4 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30036150 1.00 L3MBTL1 (0.55) L3MBTL1PARP1MPOKDM4ECYP1A2
SCHEMBL29784403 0.93 L3MBTL1 (0.49) L3MBTL1PARP1MPOKDM4ECYP1A2
SCHEMBL27729389 0.87 L3MBTL1 (0.53) L3MBTL1PARP1MPOKDM4ECYP1A2
SCHEMBL535668 0.86 L3MBTL1 (0.58) L3MBTL1PARP1MPOKDM4ECYP1A2
SCHEMBL4969655 0.85 L3MBTL1 (0.43) L3MBTL1PARP1MPOKDM4ECYP1A2
SCHEMBL28677368 0.85 L3MBTL1 (0.57) L3MBTL1PARP1MPOKDM4ECYP1A2
SCHEMBL9202046 0.84 MAPT (0.41) L3MBTL1PARP1KDM4ECYP1A2MAPT
SCHEMBL3369457 0.84 BRD4 (0.57) KDM4ECYP1A2MAPTBRD4HTT
SCHEMBL25414723 0.83 L3MBTL1 (0.55) L3MBTL1PARP1MPOKDM4ECYP1A2
SCHEMBL128967 0.83 L3MBTL1 (0.55) L3MBTL1PARP1MPOKDM4ECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4741376-A1 NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Hansoh Biomedical Co., Ltd. (CN) 2026-05-13 EP disclosed
US-12612403-B2 Nitrogen-containing heterocyclic derivative inhibitor, and preparation method therefor and use thereof SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2026-04-28 US disclosed
US-20260085045-A1 NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) 2026-03-26 US disclosed
US-20250388578-A1 NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) 2025-12-25 US disclosed
US-12497366-B2 Nitrogen-containing heterocyclic derivative inhibitor, preparation method therefor and use thereof SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2025-12-16 US disclosed
EP-4588914-A1 NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Hansoh Biomedical Co., Ltd. (CN) 2025-07-23 EP disclosed
US-12275707-B2 Modulators of mas-related g-protein receptor X2 and related products and methods ESCIENT PHARMACEUTICALS, INC. (US) 2025-04-15 US disclosed
WO-2025043094-A1 BENZOTHIA(DIA)ZEPINE COMPOUNDS FOR TREATMENT OF HBV AND HDV ASSEMBLY BIOSCIENCES, INC. (US) 2025-02-27 WO disclosed
EP-4499632-A1 QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS ESCIENT PHARMACEUTICALS, INC. (US) 2025-02-05 EP disclosed
US-20250026735-A1 MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS INCYTE CORPORATION 2025-01-23 US disclosed
WO-2011087758-A1 ADAMANTYL AMIDE DERIVATIVES AND USES OF SAME H. LUNDBECK A/S (DK) 2011-07-21 WO disclosed
WO-2011087758-A1 ADAMANTYL AMIDE DERIVATIVES AND USES OF SAME H. LUNDBECK A/S (DK) 2011-07-21 WO disclosed
WO-2011083316-A1 BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-07-14 WO disclosed
US-20110144069-A1 COMPOUNDS FOR TREATING VIRAL INFECTIONS MYRIAD GENETICS, INCORPORATED (US) 2011-06-16 US disclosed
CN-101716178-B Antitumor medicament UNIV SHANGHAI JIAOTONG 2011-06-01 CN disclosed
CN-101816659-A Anti-tumor medicament UNIV SHANGHAI JIAOTONG 2010-09-01 CN disclosed
CN-101716178-A Antitumor medicament UNIV SHANGHAI JIAOTONG 2010-06-02 CN disclosed
CN-101703507-A Antineoplastic medicament UNIV SHANGHAI JIAOTONG 2010-05-12 CN disclosed
US-20090105203-A1 COMPOUNDS FOR TREATING VIRAL INFECTIONS MYRIAD GENETICS, INCORPORATED (US) 2009-04-23 US disclosed
US-20080207573-A1 COMPOUNDS FOR TREATING VIRAL INFECTIONS MYRIAD GENETICS, INCORPORATED (US) 2008-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12612403-B2 Nitrogen-containing heterocyclic derivative inhibitor, and preparation method therefor and use thereof FAR1, NPR1, CBR1 L3MBTL1 1550/4885PARP1 3135/4885MPO 2412/4885
US-12275707-B2 Modulators of mas-related g-protein receptor X2 and related products and methods MRGPRX2, MRGPRX1, MRGPRX4 L3MBTL1 4099/4885PARP1 4425/4885MPO 2798/4885
US-20250388578-A1 NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF FAR1, NPR1, CBR1 L3MBTL1 1550/4885PARP1 3135/4885MPO 2412/4885
US-20090105203-A1 COMPOUNDS FOR TREATING VIRAL INFECTIONS HAVCR2, MAVS, CCL11 L3MBTL1 3222/4885PARP1 2033/4885MPO 103/4885
US-20250026735-A1 MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS MRGPRX2, MRGPRX1, MRGPRX4 L3MBTL1 4132/4885PARP1 4450/4885MPO 2762/4885
US-20260085045-A1 NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF NPR1, CBR1, NAT1 L3MBTL1 2282/4885PARP1 2989/4885MPO 2293/4885
US-12497366-B2 Nitrogen-containing heterocyclic derivative inhibitor, preparation method therefor and use thereof WEE1, WEE2, NOS1 L3MBTL1 4414/4885PARP1 1994/4885MPO 1144/4885
US-20080207573-A1 COMPOUNDS FOR TREATING VIRAL INFECTIONS HAVCR2, MAVS, CCL11 L3MBTL1 3222/4885PARP1 2033/4885MPO 103/4885
US-20110144069-A1 COMPOUNDS FOR TREATING VIRAL INFECTIONS HAVCR2, MAVS, CCL11 L3MBTL1 3222/4885PARP1 2033/4885MPO 103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.